US Food and Drug Administration Commissioner Robert Califf wants the conversation about clinical trial diversity to move on from simple metrics about broad demographic groups to tackle a bigger question about the realities of global clinical trials.
Key Takeaways
-
Robert Califf says pushing for clinical trials that represent the US population excludes much of the rest of the world.
“We keep talking about this as if we’re looking at overall trial participation and saying that it ought to represent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?